The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Interim report January – September 2022
The period in summary Third quarter July 1 – September 30, 2022 On July 20th, 2022 Intervacc announced that the company had received an order for the equivalent of approximately SEK 3 million from Dechra Pharmaceuticals PLC. The order concerns delivery of Strangvac®...Strangvac, a vaccine against equine strangles released for sales in Germany, France, Austria and the Benelux
Stockholm, October 12th, 2022 – Intervacc AB (publ) announces today that the first batch of Strangvac® for sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands has been released. “The first batch of Strangvac® for Germany, France, Austria,...Interim report January – June 2022
The period in summary First half year January 1 – June 30, 2022 On March 23 the first batch of Strangvac was released for sale in Sweden, and in the end of May we passed another milestone in the fight against strangles when Strangvac was released for sale in...Strangvac, a vaccine against equine strangles, is now available for sale in the UK
Stockholm, August 17th 2022 – Intervacc AB (publ) announces today that Strangvac® is now available for sale in the UK. This week Strangvac® has been launched in the UK and horse owners can now vaccinate their horses against the infectious equine disease...The CEO and a number of key personnel acquires shares through the exercise of warrants in Intervacc’s incentive program 2019/2022
Stockholm, July 26, 2022 – Intervacc AB (publ) (First North: IVACC) (“Intervacc”) announces today that the CEO, Andreas Andersson, together with three other key persons, has subscribed for 330,455 shares through the utilization of the warrants issued...Nyhetstjänster
